Lipocine Inc. — Q1 2022 Form 10-Q
Business context and reporting period
Lipocine is a clinical-stage biopharmaceutical company developing oral therapies for neuroendocrine and metabolic disorders. This unaudited report covers the three months ended March 31, 2022, with comparisons to Q1 2021. TLANDO received FDA approval on March 28, 2022; U.S. development and commercialization rights are licensed to Antares. Lipocine reported no revenue in either quarter.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.888 million | $1.581 million |
| General and administrative expense | $1.244 million | $1.534 million |
| Total operating expenses / operating loss | $3.132 million | $3.114 million |
| Net loss | $3.488 million | $3.368 million |
| Loss per share, basic and diluted | $0.04 | $0.04 |
| Cash used in operating activities | $3.885 million | $4.062 million |
| Cash, cash equivalents and marketable securities | $42.0 million at March 31, 2022 | $46.6 million at December 31, 2021 |
There is no meaningful operating margin to report because the company had no revenue. The net loss increased by about $120,000 year over year. Higher R&D spending was largely offset by lower G&A expense; other expense increased, principally because of a larger non-cash warrant revaluation loss. Cash and cash equivalents were $5.733 million, with $36.266 million in current marketable securities. Total assets were $47.604 million and stockholders’ equity was $42.410 million at quarter-end.
Investing activities provided $7.295 million, mainly from net maturities of marketable securities. Financing activities used $627,000, including $833,000 of debt repayments, partly offset by $206,000 from option exercises. No ATM shares were sold in Q1 2022. Current liabilities were $3.520 million. The balance sheet reports $1.482 million of current debt; the debt note lists $833,000 of scheduled 2022 principal, plus a $650,000 final payment charge due at maturity.
Material changes and developments
- R&D expense increased $307,000, reflecting LPCN 1148 clinical-trial activity, LPCN 1107 and LPCN 1154 studies, and LPCN 1111 manufacturing scale-up. Lower spending on the completed LPCN 1144 LiFT study partly offset the increases.
- G&A expense decreased $290,000, primarily due to lower legal costs after the 2021 Clarus settlement.
- Cash and marketable securities declined $4.6 million from year-end. Operating cash use was modestly lower than in Q1 2021, when substantial equity-offering proceeds supported financing.
- The accumulated deficit reached $176.2 million. Weighted-average shares rose to 88.3 million from 81.9 million a year earlier; loss per share remained $0.04.
- Antares received FDA approval for TLANDO. The license provides for tiered U.S. royalties, potential sales milestones, and conditional payments of $5 million in each of 2025 and 2026. No TLANDO license revenue was recognized in Q1.
Outlook, risks, contingencies and unusual items
- Management expects existing capital resources and interest to fund projected operating requirements through at least March 31, 2023, based on current plans. The company expects to need additional capital before or after that date; failure to raise funds could put its ability to continue as a going concern at risk. Expanded trials could accelerate cash use.
- Management expects continued operating losses and significant expenses as it advances LPCN 1148 and other pipeline candidates. It gave no revenue or earnings guidance.
- For LPCN 1148, enrollment in the Phase 2 study was expected to finish by the end of Q3 2022, with topline 24-week results expected by the end of Q1 2023. For LPCN 1144, the FDA recommended an end-of-Phase-2 meeting and a 72-week Phase 3 study; Lipocine said it was seeking feedback on the protocol and exploring a licensing partner.
- After quarter-end, Antares extended an option deadline to June 30, 2022 and paid Lipocine a non-refundable $500,000 fee, creditable toward a stated $4 million license fee. The filing’s descriptions of the option extension refer to TLANDO XR and also discuss LPCN 1111; investors should verify the precise scope and economics.
- After quarter-end, Lipocine amended its Clarus settlement payment schedule: it agreed to pay $1.25 million in May 2022, with no further installments. The original settlement liability was $1.5 million at March 31, 2022. The shareholder securities class action remains unresolved; the company recorded no liability because management said a loss was not probable or estimable. Insurance has a $1.25 million retention.
- The SVB loan was scheduled to mature June 1, 2022, with the final payment charge due at maturity. The loan is secured by substantially all company assets other than intellectual property and specified exclusions. The company also disclosed limited remaining authorized-share capacity and said it was seeking shareholder approval to increase authorized common shares.
- The $378,000 Q1 warrant-liability loss was non-cash and arose from fair-value remeasurement. The liability was $1.174 million at March 31, 2022. Available-for-sale securities had $67,000 of unrealized losses; the filing reported no other-than-temporary impairment.
Most important facts for investors to verify
- Whether Antares launches TLANDO and when any royalties, milestones, or other contractual payments are earned; confirm the scope of its extended option and the status of TLANDO XR and LPCN 1111.
- Whether the LPCN 1148 enrollment and Q1 2023 results timeline are achieved, and what the data show.
- Cash burn, debt repayment and maturity status, and the actual runway relative to management’s March 31, 2023 estimate.
- Availability and terms of additional financing, including shareholder approval to increase authorized shares and potential dilution.
- Outcome and costs of the shareholder class action, and completion of the amended Clarus settlement payment.